Rapid Fatal Pulmonary Complications in a Chinese Patient After Bortezomib Treatment for ALK-Negative Anaplastic Large-Cell Lymphoma

Abstract Bortezomib, a reversible proteasome inhibitor, is used for the treatment of hematologic malignancies. Common adverse events with bortezomib include gastrointestinal symptoms, thrombocytopenia, and neuropathy, whereas severe pulmonary complications have been rarely described. Herein, we pres...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2010-04, Vol.10 (2), p.152-154, Article 152
Main Authors: Zhou, Xin, Sun, Chao, Wang, Jing, Mao, Jingjue, Guo, Hongfeng
Format: Article
Language:English
Subjects:
26S proteasome
Aged
ALCL
Asian Continental Ancestry Group
Boronic Acids - adverse effects
Boronic Acids - pharmacology
Boronic Acids - therapeutic use
Bortezomib
Enzyme Inhibitors - therapeutic use
Fatal Outcome
Hematologic Neoplasms - chemically induced
Hematologic Neoplasms - enzymology
Hematology, Oncology and Palliative Medicine
Humans
Hypersensitivity
Lung - enzymology
Lung - metabolism
Lymphoma, Large B-Cell, Diffuse - chemically induced
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - enzymology
Lymphoma, Large-Cell, Anaplastic - chemically induced
Lymphoma, Large-Cell, Anaplastic - enzymology
Male
Proteasome inhibitors
Pyrazines - adverse effects
Pyrazines - pharmacology
Pyrazines - therapeutic use
Ubiquitin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Bortezomib, a reversible proteasome inhibitor, is used for the treatment of hematologic malignancies. Common adverse events with bortezomib include gastrointestinal symptoms, thrombocytopenia, and neuropathy, whereas severe pulmonary complications have been rarely described. Herein, we present a case of rapid fatal pulmonary complications in a patient with ALK-negative anaplastic large-cell lymphoma after receiving a treatment with bortezomib.
ISSN:2152-2650
2152-2669
2152-2669
DOI:10.3816/CLML.2010.n.023